Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683214 | 0.82 | BCHE (0.43) | LMNAALDH1A1SMN1; SMN2F10CYP19A1 | |
| SCHEMBL8266914 | 0.81 | F2 (0.42) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL16361758 | 0.80 | SMN1; SMN2 (0.46) | MAPTALDH1A1HTTATMSMN1; SMN2 | |
| SCHEMBL4748205 | 0.77 | NR4A1 (0.53) | MAPTALDH1A1HTTSMN1; SMN2MKNK1 | |
| SCHEMBL1027558 | 0.76 | MAPT (0.36) | MAPTALDH1A1ALOX15HTTATM | |
| SCHEMBL27338916 | 0.75 | CYP2A6 (0.44) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL85530 | 0.75 | CDC7 (0.46) | MAPTHTTCYP19A1MEN1KMT2A | |
| SCHEMBL1675775 | 0.75 | TBXAS1 (0.45) | F10MAPK14 | |
| SCHEMBL18011080 | 0.73 | MAPT (0.48) | MAPTLMNAALDH1A1ALOX15HTT | |
| SCHEMBL8337902 | 0.73 | CYP2A6 (0.49) | ALDH1A1HTTF10CYP19A1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636216-B1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-21 | — | — | EP | claimed |
| US-7741341-B2 | Benzimidazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-22 | — | — | US | claimed |
| JP-2006528213-A | — | — | 2006-12-14 | — | — | JP | claimed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | claimed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | claimed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | claimed |
| EP-1351938-A1 | PHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | claimed |
| US-9714232-B2 | Substituted piperazine compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| CN-104725359-A | Substituted piperazine compound as well as application method and application thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-06-24 | — | — | CN | disclosed |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| WO-2004035039-A1 | HETEROCYCLIC AMIDES AND THEIR USE IN TREATING THROMBOEMBOLIC DISEASES AND TUMORS | MERCK PATENT GMBH (DE) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004017963-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1368341-A1 | PHENYL DERIVATIVES 3 | MERCK PATENT GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| EP-1351938-A1 | PHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002074765-A1 | PHENYL DERIVATIVES 3 | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | HTR5A, HTR2A, HTR2C | MAPT 1187/4885LMNA 3310/4885ALDH1A1 996/4885 |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | MAPT 4847/4885LMNA 141/4885ALDH1A1 1259/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | MAPT 4843/4885LMNA 450/4885ALDH1A1 2287/4885 |
| US-20040087582-A1 | Phenyl derivatives | F2, F11, SERPINC1 | MAPT 4360/4885LMNA 2132/4885ALDH1A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.